[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiuwu Bai\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100592123",false,"NCT06989333","Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis","A Single-arm Clinical Study of Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis","aPAP and GMCSF","Inclusion Criteria:\n\n1. Age: 18 to 60 years old;\n2. A clear diagnosis of aPAP must meet at least one of the following diagnostic criteria:\n\n1\\) BALF appears \"milky white\"; Or cytological examination reveals a large amount of PAS-positive protein deposition; 2) HRCT shows typical \"paving stone-like changes\"; 3) Positive for serum GM-CSF antibody. 3. There are more than one of the following treatment indications: Symptoms such as progressive breathing difficulties, coughing, and shortness of breath after activity occur; 2) Without oxygen inhalation, PaO2 \\> 65 mmHg 3) Pulmonary function DLCO accounts for % of the predicted value, ranging from 60% to 80%, including the critical value.\n\n4\\. No other PAP specific treatments (such as WLL, inhaled GM-CSF, biological agents, etc.) have been received recently (for more than 4 weeks).\n\n5\\. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Secondary PAP (such as secondary to blood diseases, etc.);\n2. Patients with obvious pulmonary fibrosis, emphysema or irreversible lung function impairment;\n3. Patients in the acute exacerbation stage;\n4. Patients with other lung diseases (such as active pulmonary tuberculosis, bronchiectasis with purulent infection or other chronic infections; Have severe asthma, chronic bronchospasm, etc.\n5. Have a history of allergy to GM-CSF antibodies or related drug components;\n6. Patients who have participated in other clinical drug trials within the past three months;\n7. Patients who have experienced severe complications related to bronchoscopy or are intolerant to bronchoscopy;\n8. Concurrent with other serious cardiovascular and cerebrovascular diseases, hematological disorders, malignant tumors, etc.\n9. Pregnant or lactating women.","ALL","18 Years","80 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study aims to explore a new therapeutic approach: the feasibility, safety and preliminary efficacy of directly spraying GM-CSF into the airway through bronchoscopy for the treatment of aPAP.",[27],"Pulmonary Alveolar Proteinosis","NOT_YET_RECRUITING","2025-05-17",{"date":31,"type":32},"2025-05-25","ACTUAL",{"date":34,"type":21},"2025-07-01",{"date":36,"type":21},"2027-06-30",{"name":38,"class":39},"Jiuwu Bai","OTHER",""]